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Host-parasite interactions in the E. multilocularis-intermediate host model depend on a subtle balance between cellular immunity,
which is responsible for host’s resistance towards the metacestode, the larval stage of the parasite, and tolerance induction and
maintenance. The pathological features of alveolar echinococcosis. the disease caused by E. multilocularis, are related both to
parasitic growth and to host’s immune response, leading to fibrosis and necrosis, The disease spectrum is clearly dependent
on the genetic background of the host as well as on acquired disturbances of Th1-related immunity. The laminated layer of
the metacestode, and especially its carbohydrate components, plays a major role in tolerance induction. Th2-type and anti-
inflammatory cytokines, IL-10 and TGF-β, as well as nitric oxide, are involved in the maintenance of tolerance and partial
inhibition of cytotoxic mechanisms. Results of studies in the experimental mouse model and in patients suggest that immune
modulation with cytokines, such as interferon-α, or with specific antigens could be used in the future to treat patients with alveolar
echinococcosis and/or to prevent this very severe parasitic disease.
1. Introduction
The infection of the intermediate hosts by the metacestode
stage (“larval stage”) of Echinococcus multilocularis, a cestode
of the genus Echinococcus, is a good example to demonstrate
the pivotal role the host immune response plays, favoring
on one hand a partial control of infection, but yielding
also a partial impairment of its own responsiveness [1–
3]. Both tolerance and immunopathology may be observed
in Alveolar Echinococcosis (AE), the disease due to E.
multilocularis [4], and most of the mechanisms occurring
seem to be triggered by a sophisticated modulation born
out of a stage-specific parasite metabolism and respective
immunomodulating strategy.
Tolerance is essential to ensure growth and development
of the larval stage of the parasite in its host. In fact, parasite
survival relies upon a mutual tolerance of the parasite and
the host, and like all parasites, E. multilocularis modulates
and even “uses” the host’s immune system to ensure its
survival. Early killing of the parasite by the host would, of
course, not allow the larva to grow and proliferate to reach
the fertile stage (i.e., the production of protoscoleces) which
allows its passage to the definitive host and thus its “adult”
stage. Conversely, early killing of the host by the Echinococcus
sp. larvae would lead to premature death of the host, and
thus would also not allow the parasite to develop until the
production of the fertile stage of the larva. E. multilocularis
has evolved suitable strategies, at the recognition and effector
stages of the immune response, to achieve its goal: to avoid
both its premature death and the death of its host.
The immune response which develops against the larval
stages of E. multilocularis accounts for a controlled parasite
tissue development, but also for immunopathological events.
In AE, hypersensitivity and immunopathology encom-
pass several mechanisms: (1) mostly cell-related immune
reactions leading locally, in the liver and other involved
organs, to necrosis and fibrosis, (2) a rather Th2-dominated
hypersensitivity reaction, although IgE-dependent clinicals
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manifestation are rare despite a constant IgE production
by the host. Combination of epidemiological data on AE
in endemic areas with immunological findings in humans
and in experimentally infected murine intermediate hosts,
has allowed us to design an rather comprehensive picture
of the way how parasite and host survive, an understanding
that may contribute to develop new treatment strategies
comprising immune modulatory and stimulatory tools.
2. Susceptibility and Resistance of Animal
Intermediate Hosts to E. multilocularis
E. multilocularis exhibits different growth rates and mat-
uration characteristics in various species of hosts, that is,
species of rodents or lagomorphs for E. multilocularis, but
also of multiple other animal species such as swine and
primates. These differences were first assigned to differences
in strains/subspecies of the parasites; however, there is very
little variation in E. multilocularis species [5, 6]. As rodents
are the natural intermediate hosts of E. multilocularis in
the conventional parasitic cycle, differences in host immune
responses have been extensively studied in E. multilocularis
experimental infection, and actually, differences in suscep-
tibility/resistance, putatively related to respective immune
responses, do occur in different murine models [7–11].
Impairment of cellular immunity (immune suppression) is
followed by an increase in susceptibility to E. multilocularis
in experimental animals. This was shown more than 30
years ago in immunosuppressed mice by Baron and Tanner
[12] and was further demonstrated later on using SCID
mice, which were shown to be highly susceptible compared
to the wild strain and to reconstituted mice [13], and
in nude mice [14]. A similar increase of susceptibility of
experimental mice, associated with a decrease of delayed type
hypersensitivity, was also observed in mice infected with E.
multilocularis and treated with an immunosuppressive drug,
cyclosporine, which interferes with IL-2 production in T-
cells [15].
Conversely, cellular immune response against parasitic
antigens is stronger in infected resistant mice, tested either
using specific delayed-type hypersensitivity reactions in vivo
[8] or specific proliferation of lymphocytes in vitro [11].
Resistance is increased by stimulation of the cellular immune
response, as was shown with Bacille Calmette Gue´rin admin-
istration [16]. It was also shown that the antiparasitic effect
of Isoprinosine treatment in mice infected by E. mutilocularis
[17] was at least partially due to immune stimulation by this
immunomodulating agent [1].
3. Susceptibility and Resistance of
Human Hosts to E. multilocularis
Liver transplantation has been performed in patients with
very severe cases of AE since 1986. Observations in trans-
planted patients, who received immunosuppressive agents
to prevent liver rejection, confirmed the increased sus-
ceptibility to E. multilocularis growth in humans upon
impaired immune responsiveness. Increased susceptibility
was evidenced by a rapid increase in size of lung metastases,
the development of brain metastases, late re-invasion of
the transplanted liver by parasitic cell remnants, and even
early re-invasion of the transplanted liver from a spleen
metastasis [18, 19]. Similarly, a case of co-infection by E.
multilocularis and Human Immunodeficiency Virus (HIV),
leading to AIDS, has been reported, with a rapid and irre-
versible growth of E. multilocularis larvae in a young patient
[20], leading to fatality. Associated to AIDS, restoration of
immunity by appropriate antiretroviral therapy has lead to
reinstallation of the control of metacestode development
[21]. Other cases have been observed in several European
countries since then, as well as cases of AE associated with
administration of other immunosuppressive drugs for auto-
immune diseases (see [22], and personal communications
through the EurEchinoReg network). AE thus appears to be
another example of “opportunistic infection”.
In humans, a variety of clinical presentations of AE may
be seen; however, pathological features and the frequent
absence of protoscoleces suggest that, generally speaking,
humans are relatively resistant to E. multilocularis. In fact,
the implementation of mass screenings in endemic areas has
revealed that the number of established infections in humans
was far lower than the number of exposures to parasitic eggs
[23, 24]. It may be assumed that a minority of individuals
among humans (estimated to 1 out of 10 subjects) allows
the development of the E. multilocularis metacestode after
a contact with E. multilocularis oncospheres, the infectious
component produced by the adult worm in the intestine of
carnivores, which are definitive hosts [25].
The conceptual consequences of these findings in
humans, added to the observations made in experimental
rodents, cover two complementary, albeit non-mutually
exclusive, assessments: (1) natural (immunological) mech-
anisms of defence (innate or acquired) are at work in the
majority of human hosts, which are able to stop the larval
growth at the very first stages or after the beginning of
its development in the liver, (2) strategies are operating
at the parasite’s level, which may counteract the immune
system of the host and even take advantage of it for its
own growth and survival. Studies performed in experimental
animals as well as in humans with AE currently offer a rather
comprehensive picture of the main events which operate
at the very beginning of infection, when E. multilocularis
settles within the host’s liver, and at the effector stage of
the immune response, when E. multilocularis develops and
progressively invades the liver and other organs of the hosts.
These two stages will be presented successively although they
are actually linked and interdependent.
4. Role of Parasite-DerivedMolecules in
the Modulation of the Host Response in
View to Induce Immune Tolerance to
the Parasite in Its Intermediate Host
In the host-parasite interplay, metacestode surface molecules
as well as excretory/secretory (E/S) metabolic products are
considered to function as important key players (reviewed
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in [3]). The intraperitoneal murine infection model of
AE offers the opportunity to study the direct effect of
metabolic metacestode molecules on periparasitic peritoneal
cells, including especially DCs, but also other immuno-
logically relevant populations such as macrophages (M∅),
lymphocytes and other (inflammatory) cells that play a
significant role in the putative control of (or respective failure
to control) metacestode proliferation, and thus triggering
of disease development. The E. multilocularis metacestode
actively secretes or expresses molecules that putatively have
potent effects on the immune system of the murine host.
The production of these molecules and their chemical
compositions might depend on the stage of the parasite
(oncosphere, early vesicle or fully mature metacestode).
However, little is known about biological effector molecules
arising metabolically or somatically from the intrahepatic
stages of the metacestode, although various E. multilocularis
antigens, their epitopes and respective genes have been
characterized. Every parasite molecule reaching the host
environment has to pass the metacestode laminated layer.
This laminated layer is an acellular carbohydrate-rich surface
structure that protects the parasite from immunological and
physiological reactions on part of the host. Among the
main antigens described, a major carbohydrate named Em2
(G11) localizes on the surface of the laminated layer of the
metacestode [26]. Em2 is a T-cell independent antigen, and
the corresponding antibody response lacks antibody mat-
uration [27]. Another polysaccharide-containing antigen,
antigen C has been isolated and characterized from crude
metacestode extract [28]. Similar investigations have yielded
the finding of EmP2 [29, 30] and Em492 [31]. Em492 antigen
is continuously released into the exterior medium and is
also abundantly present in the parasite vesicle fluid. A sup-
pressive effect on Con-A- or crude parasite extract-induced
splenocyte proliferation in infected experimental mice was
observed upon addition of Em492 antigen [31]. Protease
treatment of Em492 antigen does not change its splenocyte
proliferation inhibitory potential, while periodate treatment
severely alters the functional properties of Em492 antigen,
indicating that the effects of Em492 antigen is mediated
through the carbohydrate part. Em492 antigen stimulates
peritoneal macrophages from E. multilocularis-infected and
–uninfected mice to produce increased levels of nitric oxide,
leading to inhibition of splenocyte proliferation. On the
other hand, Em492 antigen increases the levels of anti-CD3-
induced apoptosis, which may contribute to a decrease of
immune effector mechanisms. Another neutral glycosphin-
golipid has been identified as suppressor of human PBMCs
proliferation following stimulation by phytohemagglutinin
[32]. Hu¨lsmeier and co-workers [33] have then isolated
novel mucin-type glycoforms from the metacestode of E.
multilocularis, and these glycoforms contained mucin-type
core-I type and core-II type structures that were further
diversified by addition of GlcNAc or Gal residues. Koizumi
et al. [34] reported on the synthesis of the glycan portions
of a glycoprotein antigen of E. multilocularis in order to
elucidate the interactions between oligosaccharides and sera
of E. multilocularis-infected hosts. Stereocontrolled synthesis
of branched tri-, tetra-, and pentasaccharides displaying
400 μm
Figure 1: The laminated layer of Echinococcus multilocularis.
Scanning electron microscopic visualization of an Echinococcus
multilocularis metacestode vesicle trans-section: hollow arrow indi-
cates outer laminated layer, white arrow indicates the inner germinal
layer (Photo: A. Hemphill, IPB, Bern, Switzerland).
a Galβ1->3GalNAc core in the glycan portion of the
glycoprotein antigen was achieved, which may become an
interesting tool for further studies on their putative biolog-
ical function. With regard to metabolized proteins, an E.
multilocularis-protoscolex associated antigen of 62 kDa [35],
two 70 and 90 kDa proteins [36], and several recombinant
E. multilocularis-proteins (such as antigen II/3 [37] and its
subfragments II/3-10 [38] and Em18 [39], or EM10 [40]),
have all been published and discussed in view of a potential
biological role. However, these antigens were mainly used
to investigate respective immune responses with emphasis
on immunodiagnosis of AE, and their biological functions
have not been appropriately studied. EmAP (alkaline phos-
phatase) [41], an antigen which was shown to induce the
production of antibodies associated with disease severity
and resistance to treatment in AE patients [42], was also
shown to induce only Th2-type cytokine secretion [43].
Aumu¨ller et al. [44] used extracts from metacestodes of E.
multilocularis to induce basophil degranulation, as well as the
secretion of histamine, IL-4 and IL-13, in a dose-dependent
manner. They concluded that E. multilocularis induces a Th2
response upon IL-4 release from basophils. Siles-Lucas and
coworkers [45] identified and cloned a 14-3-3-gene of E.
multilocularis, which appeared to play a key role in basic
cellular events related to cellular proliferation, including
signal transduction, cell-cycle control, cell differentiation,
and cell survival [45, 46]. In a similar context, Kouguchi
et al. [47] identified a cDNA clone, designated EMY162,
that encoded a putatively secreted protein. EMY162 shares
structural features with the EM95 antigen, for example, 31%
amino acid sequence identity to EM95.
5. The Cross-Talk between
E. multilocularis Larvae and
Their Host through the Laminated Layer
As outlined above, the laminated layer is considered as a
barrier between the parasite and the host (Figure 1). And,
in fact, it may protect the growing larva from a direct
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contact with the immune cells of the host, and especially
the macrophages known as “epithelioid cells” that line the
border of the germinal layer at the very early stage of
parasitic development, and then the border of the laminated
layer (Figure 2(a)); in addition, it may also protect the
parasite against the attack by cytotoxic compounds such
as activated complement proteins and NO. However, as
described above, its main role in the protection of the
parasite against the immune attack from the host seems
to be mostly related to its immunomodulatory properties
which inhibit immune cell activation directly or through
the induction of immunoregulatory cytokines. Electron
microscopic examination of the laminated layer suggests
that, rather than a barrier, the laminated layer could well
rather function as a “gate” between the parasitic germinal
layer and vesicle and its host. The tegument of the germinal
layer builds up a syncytium with numerous microtriches that
protrude into the laminated layer; in addition, the release of
membranous and vesiculated structures into the matrix of
the laminated layer may be observed [3]. This “gate” could
prove to be essential to ensure a regulated traffic of various
substances between Echinococcus sp. and their hosts.
In fact, evidence of a “cross-talk” between the parasitic
larva and its host is provided by a number of observations,
the first one being the presence of high molecular weight host
proteins within the “hydatid fluid” which was demonstrated
at least 30 years ago both for E. granulosus [48, 49] and
E. multilocularis [50]. Host immunoglobulins and albumin
[48, 49, 51, 52], activators and inhibitors of the complement
cascade [50, 53] and, recently, host-derived active matrix
metalloproteinase 9, which was assumed to play a role in
the periparasitic granulomatous reactions [54], were found
in Echinococcus sp. hydatid fluid or bound to the cyst
wall.
In addition, several lines of evidence now suggest that the
larval development of E. multilocularis is triggered by cell
signaling originating from the intermediate host [55, 56].
The phosphorylation of EmMPK1, a parasitic orthologue
of the Extracellular signal Regulated Kinase (ERK) MAPK,
is specifically induced in in vitro-cultured E. multilocularis
metacestode vesicles, in response to exogenous host serum,
hepatic cells and/or human epidermal growth factor (EGF).
The E. multilocularis metacestode is thus able to “sense” host
factors which results in an activation of the parasite MAPK
cascade [57]. Cross-functioning between parasite-derived
molecules and host liver was also described for parasite-
derived enzymes: for instance, E. multilocularis-derived
transglutaminase was shown to efficiently catalyze human
liver-derived osteonectin cross-linking [58]. The fact that
tissue-dwelling E. multilocularis expresses signaling systems
with significant homologies to those of the host raises the
highly interesting question whether cross-communication
between cytokines and corresponding receptors of host and
parasite can occur during an infection, that is, whether
the parasite may also influence signaling mechanisms of
host cells through the secretion of various molecules which
might bind to host cell surface receptors. Such interactions
could contribute to immunomodulatory activities of E. mul-
tilocularis or be involved in mechanisms of organotropism
and/or in host tissue destruction or regeneration during
parasitic development. In a recent preliminary study, a
significant influence of E. multilocularis metacestode on the
activation of MAPKs signalling pathways was found in the
liver cells both in vivo in infected patients and in vitro in
cultured rat hepatocytes [59]. Significant changes in JNK
phosphorylation was observed in hepatic cells in vivo, using
hydatid fluid which contains a significant amount of host
proteins. They were also observed using supernatant from
axenic cultures of E. multilocularis, which is totally free of
host components. This observation suggests that parasitic
components, and not only factors from host origin, were
actually acting on hepatocyte metabolic pathways.
It is possible that vesicle fluid from E. multilocularis,
in addition to the already recognized proteins listed above,
may also contain cytokines and growth factors from host
origin and serve as storage for continuous release of factors
both to the parasite and to the host through the laminated
layer which appears critical at the host-parasite interface [3].
Dual interactions could thus ensure growth and survival
of the parasite while interfering with host liver cells. As
some of the cytokines which were proven to be important
immunoregulatory factors leading to sustained tolerance,
such as TGF-β, are quite important in the balance between
cell proliferation and death/apoptosis, it may be suggested
that the laminated layer could play a role similar to that of
the placenta at the materno-foetal interface [60]: ensuring
parasite growth and hepatic cell homeostasis while ensuring
proper immune tolerance. Indeed, the E. multilocularis
metacestode is sensitive to TGF-β signaling [61, 62] and
the metacestode ERK-like kinase, EmMPK1, phosphorylates
EmSmadD, a metacestode analogue of the Co-Smads of
the TGF-β signaling pathway [63]. This is a novel and
important field of research to understand better the subtle
Echinococcus/host cross-talk and the complex triggering of
the tolerance process.
6. Cells and Mechanisms Involved at the Early
Stage of E. multilocularis Infection
At the time of initial encounter with its murine host, the
metacestode might modulate the immune response. The
changes that it induces are dynamic and depend on the
stage of development, for example, ranging from oncosphere,
to early stage vesicles up to a fully maturated and fertile
metacestode. Dendritic cells (DCs) and macrophages (M∅s)
are among the first cells encountered by the parasite,
which, by secreting and expressing certain molecules, has
evolved mechanisms to suppress the major inflammatory
and thus immunopathological pathway. Interaction of par-
asite metabolites with Toll-like receptors (TLRs) and C-
type lectin receptors (CLRs) that are expressed largely, but
not exclusively, on DCs and M∅s is assumed to result
in phenotypic changes and modification of the cytokine
profiles produced by these cell types, but this has not yet
been experimentally shown at the early post-oncospheral
stage of infection of murine AE. Several experiments have
suggested that E. multilocularis, either by cell-cell contact or
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by its products, could inhibit and/or modulate the immune
response at the very early stage of antigen presentation to T-
cells. E. multilocularis was shown to modify the accessory cell
function and interfere with antigen presentation through a
parasite-derived macrophage modifying factor [64]. It was
also shown that immature dendritic cells of human origin
did not mature and had a reduced capacity to take up
dextran via mannose receptors in the presence of crude
non-fractionated E. multilocularis antigen; however, further
maturation could be induced by proinflammatory cytokines;
these mature dendritic cells, pulsed with E. multilocularis
antigen, were slightly better inducers of T-cell proliferation
than non-pulsed dendritic cells [65].
E. multilocularis-infected mouse macrophages as anti-
gen-presenting cells exhibit a reduced ability to present
a conventional antigen to specific responder lymph node
T-cells when compared to normal macrophages [66]. Co-
stimulatory signals are crucial for T-cell activation and it
is well known that failure in the expression of one of the
components of the receptor-ligand pairs may severely impair
T-cell activation and induce tolerance by a mechanism
generally called “anergy”. In the above mentioned exper-
iment, using macrophages from E.multilocularis-infected
mice, B7-1 (CD80) and B7-2 (CD86) remained unchanged,
whereas CD40 was down-regulated and CD54 (=ICAM-1)
slightly up-regulated. FACS analysis of peritoneal cells
revealed a decrease in the percentage of CD4+ and CD8+
T-cells in E. multilocularis-infected mice. Taken together, the
obstructed presenting activity of E. multilocularis–infected
host macrophages appear to trigger an unresponsiveness of
T-cells leading to the suppression of their clonal expansion
during the chronic phase of AE infection [66].
By inducing functional changes in DCs and M∅s, the
metacestode can achieve important shifts in T-cell subsets.
An initial acute inflammatory Th1 response is subverted
gradually to a Th2 response during the chronic phase of AE.
Cytokines, such as IL-4, IL-5, IL-9 and IL-13, secreted largely
by immune-cell types in response to parasite antigens, not
only down-modulate the Th1 response but can also promote
parasite expulsion and tissue renewal and repair [67]. The
metacestode most likely achieves the Th2 expansion through
the induction of regulatory cytokines, such as IL-10 and
TGF-β [68]. As mentioned above, in murine AE, the cell-
mediated immune response of the host plays an important
role in controlling metacestode proliferation.
7. Cytokines Involved in the T-Cell
Activation Stage of Immunity after
E. multilocularis Infection
7.1. Th2 Cytokines. Cytokine profiles, due to the secretion of
characteristic cytokines by (mostly but not only) T “helper”
(Th) cells give an insight into immune mechanisms involved
in host-infectious organism relationship and in the types
of immune responses that are developed after the early
stage of antigen and “pattern” recognition. Th1-cytokines
[Interleukin- (IL-)2, Interferon- (IFN-γ)] are induced by
Il-12 and mostly involved in T-cell-mediated cytotoxicity;
Th2-cytokines (IL-4, IL-5, IL-13) are induced by IL-4,
and mostly involved in antibody-mediated non-cytotoxic
immune responses; TH17-cytokine (IL-17) is induced by
IL-23, modulated by IL-21 and IL-22 and TGF-β, and
mostly involved in T-cell-mediated activation of innate
immunity/inflammation, but also in tolerance [69].
High levels of Th2 cytokines are observed, including
IL-4, IL-13 and IL-5, in addition to a relatively low level
of secretion of IFN-γ, in patients with AE [70, 71], and
in E. multilocularis infected mice [72]. Production of IL-
5 by PBMCs, and among those very specifically by CD4 T
lymphocytes, is induced by Echinococcus antigens not only in
patients with AE but also in normal subjects [71]. Secretion
of IgE and IgG4 antibodies is associated with the Th2 profile.
Total IgE and specific IgE and IgG4 against E. multilocularis
antigens are highly elevated in those patients with the most
aggressive disease [73]. Disappearance of IgE and decline
of IgG4 specific antibodies are significantly associated with
regression of the lesions in patients treated with antiparasitic
drugs, and both Th2-related antibody isotypes are the first to
disappear after surgical cure [74, 75]; this represents indirect
evidence of the prominent stimulation of Th2 cytokines by
the viable parasite at a chronic stage.
In the experimental mouse model, a Th2 profile is also,
globally, the hallmark of Echinococcus sp. infections at the
chronic stage. In mice experimentally infected with E. multi-
locularis, three stages of cytokine secretion can be identified:
(1) a first stage of Th1 cytokine secretion including IL-2 and
IFN-γ, associated with a slow parasite growth; (2) a second
stage characterized by a mixed secretion of Th1 and Th2
cytokine secretion, especially IL-5 and IL-10, associated with
rapid parasite growth; and finally (3) a last stage of immune
suppression with a nearly complete inhibition of lymphocyte
proliferation and of cytokine secretion following specific or
non-specific stimulation [76].
7.2. Cytokines Leading to Tolerance. The main cytokines
involved in immune tolerance are IL-10 and TGF-β. Most of
the studies in AE as well as in the experimental models have
first focussed onto IL-10. The anti-inflammatory properties
of IL-10 are well known, especially through the inhibition of
macrophage activation and cytotoxic functions [77].
Spontaneous secretion of IL-10 by the PBMCs is the
immunological hallmark of patients with progressing lesions
of AE [71]. Conversely, IL-10 is significantly lower in patients
with abortive lesions [78]. IL-10 is measurable in the serum
of the patients with AE at higher concentrations than in
control subjects [79]. A variety of cell types are involved in
the secretion of IL-10 by resting and stimulated PBMC in
patients with AE, especially CD4 and CD8 T-cells, but also
non-T non-B cells [71]. “Suppressor” CD8 T-cells, induced
by parasite products, were reported to be involved in toler-
ance to E. multilocularis [80, 81]. However, the relationship
between the capacity of these cells to secrete IL-10 and their
“suppressor” activity is unknown. A preliminary report has
confirmed that locally, in the periparasitic granuloma, T-cells
secreted IL-10 and the data suggest that IL-10 production is
highest closer to the parasitic vesicles [82]. After experimen-
tal infection with E. multilocularis, IL-10 secretion by spleen
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cells is slightly delayed and is part of the cytokine profile
observed in the second phase of E. multilocularis growth [76].
Similar changes were also observed when measuring IL-10
levels in the serum of infected mice: they remained low before
80 days post-infection and then increased sharply at 100 days
post-infection when they reached a peak [83].
The presence of TGF-β secreting cells in the periparasitic
granuloma surrounding E. multilocularis vesicles in the liver
of patients with AE has been recognised only very recently
[68] and exploring TGF-β in its multiple functions in E.
multilocularis infection is still an open field of research.
To our knowledge, no information is available on the
production of TGF-β by PBMCs in AE. Evidence of TGF-
β production in experimental E. multilocularis infection
is given by a recent study on the effect of combined
pentoxifylline and albendazole on parasite growth: with this
combination the inhibition rate of cyst growth was 88% and
was associated with a marked decrease of IL-10 and TGF-β
which were elevated in control mice [84].
7.3. Pro-Inflammatory Cytokines and Chemokines. All studies
on the cytokine profile in AE, in humans and in the
experimental models, have stressed that it was never a “pure”
Th2 profile, but always a rather mixed profile, including the
so-called “Th0” profile, even in late stages of the disease.
Significant amounts of Th1 cytokines such as IL-2, IL-12,
IFN-γ, as well as pro-inflammatory cytokines (IL-1, TNF-α,
and IL-6) have been found to be secreted by peripheral blood
mononuclear cells in most studies in humans infected by E.
multilocularis. However, the relative ratios of these cytokines
as well as of the chemokines produced when PBMCs from
patients are cultivated with parasitic antigens give a rather
complex picture. A recent study showed that production
of the proinflammatory cytokines IL-1α and IL-18 by E.
multilocularis vesicle antigen-stimulated PBMC was reduced
in AE patients, regulatory IL-10 was similar, but parasite
vesicle-induced IL-8 was dominant and clearly elevated
in patients [85]. Such selective and opposite dynamics of
inflammatory cytokines and chemokine release may prevent
pathogenic inflammation, and constitute an appropriate
response for attraction of effector cells into the periparasitic
tissues with the capacity to limit E. multilocularis metaces-
tode proliferation and dissemination.
In the experimental model of secondary infection in
mice, the levels of Th1 cytokines as well as pro-inflammatory
cytokines was initially elevated, and then progressively
decreased while Th2 cytokines and IL-10 increased [76].
Unfortunately, nothing is known on the involvement of
Th17, IL-17 secreting T-cells, and of IL-21, -22 and -23
in the development of immune cell infiltration around
the parasitic vesicles and their relationship with immuno-
regulatory cells in echinococcosis. This newly recognised
subset of T helper cells appears to be essential for the devel-
opment of T-cell-derived inflammatory reactions (delayed-
type hypersensitivity reactions and granuloma-type patho-
logical pictures) [69]. No doubt that this discovery opens a
new and exciting field of research to better understand the
tolerance/cytotoxicity balance and time-course in AE. The
recruitment and presence of all potential actors of Th17-
driven immune reaction in the lesions highly suggests that
the IL-23/IL-21/IL-22/IL-17 pathway is actually operating in
echinococcosis; however, it has to be formally demonstrated
and its modulation/inhibition by the regulatory cytokines
should be carefully studied.
Attempts at enhancing Th1-related immune responses
have resulted in increased resistance to E. multilocularis
infection in experimental mice. Treatment with IFN-γ either
before or after experimental infection has been shown to be
only partially effective in reducing larval growth, although
it was able to moderately increase the periparasitic fibrotic
process [86]. Conversely, pretreatment of mice with IL-12 is
extremely efficient in preventing the development of lesions
and leads to abortive parasitic vesicles surrounded by fully
efficient periparasitic immune cell infiltration and fibrosis
[87]. IFN-α is also able to prevent larval growth in exper-
imental mice [72]. Associated with this preventive effect of
IFN- α, a significant modulation of cytokine secretion, with
a significant decrease in IL-13 and increase in IFN-γ by
peritoneal macrophages and spleen cells was observed in the
treated mice [72]. Isolated attempts of treatment with IFN-γ
in patients at a late stage of AE were no more successful than
those performed in experimental mice and they could not
modify host’s cytokine profile significantly [88]. Conversely,
IFN-α was shown to favour the regression of AE lesions
while reversing the abnormal Th2-skewed cytokine profile in
a patient with AE [89].
8. Effector and Regulatory Cells and
Mechanisms in E. multilocularis Infection
Anti-inflammatory cytokines do interfere in T helper/
regulatory/cytotoxic lymphocyte differentiation. In patients
with AE, long after the initiation of the disease, the genera-
tion of memory Th1 CD4+ T-cells was shown to be impaired
[90]. Furthermore, in such patientsa biased CD4/CD8 T-cell
ratio is observed: a marked increased of the CD4/CD8 ratio,
mainly due to a decreased number of CD8 T-cells among
peripheral T lymphocytes, and the predominance of CD8 T
lymphocytes within the periparasitic granuloma characterize
“susceptible” patients with a severe and progressing disease
[91] (Figure 2(b)). In patients with progressing/severe AE,
CD8-T-cells have been shown to produce Th2 cytokines as
well as IL-10 and TGF-β [68, 71, 92]. In infected mice, the
first two stages of cytokine production are also characterized
by differential infiltration of the periparasitic liver with CD4,
and then CD8 T lymphocytes, following different kinetics in
resistant versus susceptible mice [9].
In addition, cytokines and other mechanisms may play a
role in specifically inhibiting effector immune mechanisms,
and particularly cytotoxicity mediated by cells of the innate
immune response (NK cells, macrophages) and by cells of the
adaptive immune response (cytotoxic T-cells). The crucial
role of macrophages in the effector phase of the immune
response towards E. multilocularis has been reported, and
their stimulation results in enhanced parasite killing and
protection of the host [25, 93]. On the other hand, an impair-
ment of chemotactic and phagocytic properties of cells of
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Figure 2: Cells of the periparasitic granuloma in E. multilocularis infection in humans; immunostaining of liver sections of patients with
alveolar echinococcosis. (a) the “epithelioid cells” (EC) are CD68+ macrophages with an epithelium-like arrangement, located at close
contact to the laminated layer of the parasitic vesicle (PV); (b) CD8+ T-cells represent the major cell population of the periparasitic infiltrate;
(c) infiltration by CD3+ T-cells is especially prominent around the new vessels (V) developed at the periphery of the granuloma, at the
border of the invaded liver parenchyma (LP); (d) most of the infiltrating T-cells express TGF-β. (Photo: B. Kantelip and DA Vuitton, WHO-
Collaborating Centre; Universite´ de Franche-Comte´, Besanc¸on, France).
the phagocytic system has been shown in E. multilocularis
hosts [72, 94, 95]. This suggests that anti-inflammatory
effects, mediated by cytokines, are actually operative at
the systemic level. A crucial- and ambiguous- role of
macrophages regarding NO secretion has been disclosed
in murine E. multilocularis infection. In fact, NO may be
both cytotoxic against parasites and immuno-modulatory by
inhibiting cell activation. Both were found to be operating
and it was especially demonstrated that the high periparasitic
Nitric Oxide (NO) production by peritoneal exudate cells
contributed to periparasitic immunosuppression [96, 97];
this explains why, paradoxically, iNOS deficient mice exhibit
a significantly lower susceptibility towards experimental
infection [98].
Contact inhibition of effector macrophages could be
induced either by anti-inflammatory cytokine secretion or,
more directly, by germinal layer-derived molecules through
the laminated layer. Analysis of the cell surface markers of
the epithelioid macrophages lining the parasitic vesicles in
humans (Figure 2(a)) has shown a very unusual expression
of these markers, particularly a high expression of CD 25,
the inducible chain of the IL-2 receptor, a chain usually
only expressed by activated T-cells and especially CD4 T-
regulatory cells [99]. Such an abnormal expression of CD
25 on macrophages has been shown in other granulomatous
diseases and could be related to a particular functional state
of the macrophages, either involved in tolerance induction or
inhibited in its cytotoxic properties, or both.
NK- and/or T-cell-dependent cytotoxic mechanisms may
be impaired by the cytokines secreted abundantly in the
periparasitic immune cell infiltrate and/or through cell-
cell interaction mechanisms. The quasi-absence of NK cells
and the inhibition of the expression of the co-stimulatory
receptor NKG2D at the surface of CD8-T-cells in the
periparasitic granuloma has been shown in patients with AE.
Despite the presence of its ligand, MICA/B, at the surface of
hepatic cells, epithelioid cells and of the parasite germinal
layer itself, cytotoxicity of CD8 T-cells might thus be severely
impaired [68]. The lack of expression of NKG2D on CD8
T-cells was not related to the presence of the soluble form
of MICA/B, since this soluble form could not be detected
in these patients. A role for TGF-β is highly likely since it
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was massively expressed by the lymphocytes surrounding the
parasitic vesicles (Figure 2(d)).
Characterisation of regulatory cells is just at its beginning
in E. multilocularis infection. An important role of CD4+
CD25+ T-regulatory cells has been suggested by a recent
study in patients with AE [85]. Such a phenotype is
quite characteristic of T-regulatory cells and they are likely
responsible, at least partially, for the secretion of the anti-
inflammatory/tolerogenic cytokines, such as IL-10 which
is constantly elevated in AE patients. In this study, an
increased number of CD4+ CD25+ T-cells was observed in
the patients, compared to healthy controls. In the same study,
after 48 h of co-culture, E. multilocularis metacestode culture
supernatant and E. multilocularis vesicles depressed the
release of the pro-inflammatory cytokine interleukin (IL)-12
by PBMC. This effect was dose-dependent and a suppression
of tumour necrosis factor (TNF)-α and IL-12 was observed
even when PBMC were activated with lipopolysaccharide
(LPS). Comparing proinflammatory cytokine release by AE
patients and controls showed that the release of IL-12 and
TNF-α was reduced in AE patients, and was accompanied by
a reduced release of the Th2-type chemokine CCL17 (thymus
and activation regulated chemokine, TARC), suggesting an
anti-inflammatory response to E. multilocularis metacestode
in AE patients.
9. Relationship between the “Delayed Type
Hypersensitivity” Responses and Local
Pathological Events/Clinical Presentation,
Signs and Symptoms in AE
Despite the tolerance that is exerted to protect the parasite
against host’s immune defences, effector mechanisms are
nevertheless present. They are responsible for the attraction
of various types of immune cells to the site of larval
growth, and especially to the infected liver. “Delayed-type
hypersensitivity reactions”, the immune effector mechanisms
also known as “type IV” hypersensitivity, are characterised
by immune cell recruitment, tissue infiltration, and neo-
angiogenesis, followed by necrosis and fibrosis. Involvement
of such reactions is particularly striking in AE, where
chronically established larval development is characterized
by a sustained infiltration of the host’s immune cells which
becomes organised as a “granuloma” and associated with
necrosis and fibrosis [9, 91]. Granulomatous reactions are
typical of delayed-type hypersensitivity reactions that are
not fully efficient. Their association with histopathological
characteristics such as “giant cells” (macrophages with
multiple nuclei) and calcifications (which are the ultimate
outcome of macrophage activation) is unique. Such gran-
ulomatous reactions contribute to the immunopathological
events responsible for some of the complications of the
underlying diseases, as observed in tuberculosis, leprosy,
leishmaniasis or schistosomiasis.
Necrosis of the lesions is one of the hallmarks of AE in
humans. In the liver, expression of IL-1, IL-6 and TNF-α
mRNAs were observed in macrophages at the periphery of
the granuloma in all studies patients, and close to the para-
sitic vesicles in patients with severe diseases and pathological
pictures of lesion necrosis [99]. TNF-α could thus contribute
to the necrotic process which gives the typical ultrasound and
CT-scan pictures of AE, and leads to several complications
in patients with AE. However, TNFs represent also a major
factor to prevent metacestode growth, as is exemplified by
the exacerbation of E. multilocularis metacestode growth
in transgenic mice deficient for Lymphotoxin and TNF-α
[100].
Fibrosis is also a hallmark of AE, leading to a complete
disappearance of the liver parenchyma and to the death
of the metacestode, with vesicles embedded in an acellular
tissue composed nearly entirely of cross-linked collagens
[101]. The diffusion of the fibrotic process even far from the
parasitic lesions strongly suggests a major role for cytokines
in collagen synthesis. They may also be involved in cross-
linking the collagen bundles in humans [58, 101–104], as
well as in the experimental models [10]. TGF-β, present
in the cell infiltrate surrounding the parasitic lesions, in
addition to its role in maintaining tolerance, is likely involved
in the development of fibrosis in AE; however, this has
never been studied until now. The parasite itself could also
be involved in the collagen cross-linking process, since a
transglutaminase of parasitic origin has been shown to be
strongly expressed in and at the border of the parasitic
vesicles and is able to efficiently cross-link collagens of
human origin in vitro [58]. Development of fibrosis has been
shown to be either quantitatively or qualitatively correlated
to protection in experimental animals [10, 86], and is thus,
usually, considered to be beneficial to the host. Fibrosis, in
addition to the laminated layer, could be responsible for
the protection of the parasite against any contact with both
cytotoxic and antibody-secreting cells of the host and vice-
versa. It may explain the low rate of anaphylactic symptoms
in patients with AE [104, 105]: the extremely fibrotic lesions
of AE cannot rupture, and the echinococcal fluid may well
be never in contact with mast cell-bound IgE, despite their
constant presence, which could be demonstrated in vitro
[104]. In fact allergic symptoms rarely occur in patients
with AE, only while parasitic cells are migrating to other
organs than the liver and are eventually leading to metastases,
especially through pulmonary embolism [105]. However,
fibrosis is also the main cause for bile duct and vessel
obstructions and thus, the pathophysiological background
of chronic cholestasis, angiocholitis, portal hypertension,
Budd Chiari syndrome and/or vena cava obstruction [105].
It may also be one of the reasons for the poor transport of
antiparasitic drugs to the lesion.
One of the striking features observed in experimental
murine AE (and also in naturally acquired AE of humans
[104, 105]) is the absence of hypereosinophilia, a common
feature of helminth-related diseases. The mobilization of
eosinophils is known to be a crucial immunological event
that plays an important role in the host defense against
helminths. Eotaxin, a CC-proinflammatory chemokine, is
one of several described chemoattractants for eosinophils.
In addition, also IL-5 may mobilize these cells [106] but
its role remains controversial. Eosinophils possess granules
containing a variety of toxic molecules [major basic protein
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(MBP), peroxidase, neurotoxin, histaminase and others]
which are active against many multicellular parasites, in
particular helminths [107]. In many examples of nema-
tode infections, eosinophilia is a marked characteristic,
and eosinophils directly cause profound damage to the
tegument of the worms, in which a marked reduction
of fertility and longevity is observed [108]. On the other
hand, IL-5 and eosinophils have no detectable effects on
the infection with selected cestodes or trematodes [109].
An extravasation of eosinophils causing eosinophilia in the
peritoneal cavity has been demonstrated to be beneficial for
the host by causing damage to the immigrant immature
worm of Fasciola hepatica, resulting in the erosion of the
tegumental syncytium [110]. Recently it could be shown
that metacestode antigens (VF and E/S) exhibit proteolytic
activity on eotaxin in vitro [111]. Inhibition of eotaxin
activity may suppress the mobilization of eosinophils in
E. multilocularis-infected hosts. Eotaxin is considered one
of the main activators and chemo-attractants of resident
eosinophils [112]. In experimental murine AE, the detected
eotaxin inactivation by VF and E/S products may contribute
to explain the absence of eosinophils within the peritoneal
cavity of AE-secondary infected mice. Absent eosinophils
thus may be a part of a series of events that maintain
a low level of inflammation in E. multilocularis-infected
hosts.
Finally, angiogenesis is one of the aspects of the peripara-
sitic cell-mediated immune reactions which have been most
neglected in the immuno-pathological studies of echinococ-
cosis. Immunostaining of extracellular matrix proteins in the
periparasitic areas of E. multilocularis infections have shown
impressive pictures of neo-angiogenesis in the periparasitic
granuloma [10, 101]. Angiogenesis is likely involved in
the traffic of immune cells to and from the lesions; T-
cells are especially numerous around the neo-vessels at
the periphery of the periparasitic granuloma (Figure 2(c)).
It may also explain some aspects of AE imaging, with a
delayed reinforcement of the periphery of the lesions at
CT-scan after injection [113] and an uptake of fluoro-
deoxyglucose on PET-scan images [114]. Last but not least,
as observed in malignant tumours, it may also be involved in
the metastatic process observed in AE, a major component
of the severity of this disease. Preliminary unpublished
observations suggest that angiogenesis could be promoted by
cytokine-like substances secreted by the metacestode itself.
10. Role of Host Immunogenetics in
the Balance between Tolerance and
Effector/Hypersensitivity Mechanisms
The role of some specific parasite-derived substances/
antigens for the final orientation of the immune response
and the relative importance of cell-mediated effector
immune response versus tolerance in Echinococcus sp. infec-
tion is ambiguous. Until the beginning of the 1980s, every
exposure to E. multilocularis oncospheres was believed to
be followed by larval development and occurrence of the
disease. A more careful evaluation of epidemiological data
in humans and animals in the same endemic areas first
questioned this assumption [115, 116]. Then the imple-
mentation of mass screening in endemic areas revealed that
the number of serologically “positive” cases were far higher
than that of patent cases, disclosed by liver ultrasonography
[23, 24, 117]. Positive serological results in individuals living
in endemic areas (i.e., subjects with specific antibodies
against E. multilocularis and who share the same risk factors)
may account for at least 4 different situations: (1) “patent”,
overt disease with symptoms, (2) “latent”, non-apparent
disease, (3) calcified dead lesions in the liver and (4) no
apparent lesions [2]. The clustering of subjects with specific
antibodies in those areas where the number of “patent” cases
is highest strongly suggests that these subjects actually had
contacts with the parasite in the previous years. Some genetic
factors have been found to associate with these various
outcomes in humans. There is a significant association
between HLA DR 11 and protection, HLA DPB1∗0401 and
susceptibility, and HLA DR3 and DQ2 and severe clinical
evolution of the disease [118]. The HLA B8, DR3, DQ2
haplotype is observed with an unusual frequency in patients
with autoimmune diseases characterised by an increased and
inappropriate humoral immunity and a relatively inefficient
cellular immune response. In fact, studies on cytokine
secretion by PBMC from HLA DR3+, DQ2+ patients with
AE, compared with patients without this HLA haplotype,
have shown that the spontaneous secretion of IL-10 was
much higher in HLA DR3+, DQ2+ patients [43]. A limited
number of family cases have been observed in endemic areas
that suggest an inherited pattern in populations which share
the same risk factors [119]. Preliminary data indicate that
relatives with progressive forms of E. multilocularis infection
shared both HLA haplotypes and the associated clinical
presentation of the disease [120]. Other genes within the
MHC that are known to be related to the initiation and/or
the effector phase of the immune response could also be
involved. No significant correlation was observed between
occurrence and/or severity of the disease and polymorphism
in TNF promoter gene. However, 63% of 94 patients with AE
from the same European endemic area as mentioned above
had the homozygote Thr-Thr form of the TAP2 665 codon
site, versus 45% of controls [121].
11. Conclusion
Results of observations in humans and experimental studies
in animals suggest that, in the absence of fully effective anti-
parasitic chemotherapy for AE, modulation of the host’s
immune response could be envisaged to fight against the
parasite and to prevent the disease and/or its complica-
tions. As shown above, recombinant IFN-α2a would be the
best “immunological drug” candidate. Other approaches
are based on the use of specific antigenic components
of Echinococcus sp. as preventive or therapeutic vaccines
[122–124]. The Eg95 vaccine has already reached field
validation for its use in E. granulosus infection of sheep
[125], and similar or novel antigens could be adapted to
E. multilocularis infection of intermediate hosts. In murine
AE, preliminary experimental reports suggest that several
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antigenic compounds may provide good protection against
primary infection, for example, Em14-3-3 [122], Em95
[123], EMY162 [126] and EmTetraspanin [124]. Dependent
of the economical and ethical feasibility of such an approach,
a preventive vaccine for E. multilocularis infection in humans
may theoretically be envisaged, while a therapeutic approach
still deserves further detailed investigation.
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